Champions Oncology announced the appointment of Angela Davies, M.D., as Chief Medical Officer. Dr. Davies has demonstrated leadership and success in both academic clinical practice and as an executive in the pharmaceutical industry. Previously, she was Chief Medical Officer of OSI Pharmaceuticals where she led the clinical development program for Tarceva(R) (erlotinib), as well as other pipeline products, until the company's acquisition by Astellas Pharma.

Earlier in her career she was an Associate Professor of Medicine at the University of California, Davis, where she practiced as a medical oncologist and was a principal investigator on NCI sponsored and investigator initiated clinical trials, specializing in thoracic malignancies and development therapeutics. Dr. Davies most recently served as Chief Medical Officer of Novocure, where she was responsible for the company's global clinical development and medical safety programs, and worked closely with the Global Commercialization Team in launching a newly approved medical device for the primary brain tumor, recurrent glioblastoma.